Sham Injection + Recombinant human hyaluronidase PH20 + Insulin aspart + Insulin lispro
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 1 Diabetes Mellitus
Conditions
Type 1 Diabetes Mellitus
Trial Timeline
Dec 1, 2011 → Sep 1, 2013
NCT ID
NCT01526733About Sham Injection + Recombinant human hyaluronidase PH20 + Insulin aspart + Insulin lispro
Sham Injection + Recombinant human hyaluronidase PH20 + Insulin aspart + Insulin lispro is a approved stage product being developed by Halozyme Therapeutics for Type 1 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT01526733. Target conditions include Type 1 Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Type 1 Diabetes Mellitus were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01526733 | Approved | Completed |
Competing Products
20 competing products in Type 1 Diabetes Mellitus